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Abstract
Venezuelan equine encephalitis virus (VEEV) belongs to the Alphavirus genus and several species of this family are
pathogenic to humans. The viruses are classified as potential agents of biological warfare and terrorism and sensitive
detection as well as effective prophylaxis and antiviral therapies are required. In this work, we describe the isolation of the
anti-VEEV single chain Fragment variable (scFv), ToR67-3B4, from a non-human primate (NHP) antibody gene library. We
report its recloning into the bivalent scFv-Fc format and further immunological and biochemical characterisation. The scFv-
Fc ToR67-3B4 recognised viable as well as formalin and ß-propionolactone (ß-Pl) inactivated virus particles and could be
applied for immunoblot analysis of VEEV proteins and immuno-histochemistry of VEEV infected cells. It detected specifically
the viral E1 envelope protein of VEEV but did not react with reduced viral glycoprotein preparations suggesting that
recognition depends upon conformational epitopes. The recombinant antibody was able to detect multiple VEEV subtypes
and displayed only marginal cross-reactivity to other Alphavirus species except for EEEV. In addition, the scFv-Fc fusion
described here might be of therapeutic use since it successfully inactivated VEEV in a murine disease model. When the
recombinant antibody was administered 6 hours post challenge, 80% to 100% of mice survived lethal VEEV IA/B or IE
infection. Forty to sixty percent of mice survived when scFv-Fc ToR67-3B4 was applied 6 hours post challenge with VEEV
subtypes II and former IIIA. In combination with E2-neutralising antibodies the NHP antibody isolated here could
significantly improve passive protection as well as generic therapy of VEE.
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Introduction
Venezuelan equine encephalitis virus (VEEV) belongs to the
Alphavirus genus within the Togaviridae family and was first
isolated from horses in the 1930s [1,2]. Besides equids, several
species of this virus family are also pathogenic to man and are
recognized as potential agent of biological warfare and biological
terrorism. VEEV is listed as a ‘‘Dirty Dozen agent’’ and is
classified as Category B agent by the Centers for Disease Control
and Prevention, Atlanta (http://emergency.cdc.gov/agent/
agentlist-category.asp). The virus is highly infectious by the aerosol
route [3] and an intentional release as a small-particle aerosol may
be expected to infect a high percentage of individuals within an
area of a least 10,000 km
2 [4]. Moreover, VEEV is responsible for
VEE epidemics that occur in South and Central America [5–7]. It
is a single stranded positive-sense RNA virus and is maintained in
a cycle between rodents and mosquitoes in nature. VEEV
represents a complex of viruses previously classified as subtypes I
to VI. However, recent taxonomic changes have classified only the
subtype I viruses as VEEV and differentiate five distinct variants
(IA/B, IC, ID, IE, IF; http://ictvonline.org). Mainly the subtypes
IA/B, IC and ID have been proven to be pathogenic for man. The
disease they cause, ranges from mild febrile reactions to fatal
encephalitic zoonoses and outcomes are significantly worse
especially for young and elderly patients. Subtypes II–VI are
now classified as distinct species (http://ictvonline.org) and
especially Everglades and Mucambo virus (formerly subtypes II
and IIIA) share a high level of genetic homology to VEEV and
cause a similar human disease that may lead to encephalitis and
death in a small proportion of cases [8].
Continued effort has been made to develop highly-sensitive
monoclonal antibodies as well as recombinant antibodies for the
immunological detection and diagnosis of VEEV [9–15]. More-
over, different well established identification principles like for
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immunoassays have been evaluated for the detection of VEE
viruses [9–11,16–20].
Two live, attenuated vaccines, TC-83 [21] and V3526 [22]
were developed to prevent disease caused by VEEV, Everglades
virus and Mucambo virus [23–27] but both formulations caused
unacceptable levels of reactogenicity to allow for general licensure
[23,28,29–32].
A rather uncertain alternative to live attenuated vaccines are
formalin inactivated vaccines against viral equine encephalitis.
These vaccines do not produce any adverse side effects but have
the disadvantage that they are of limited potency and available for
humans at high risk only. The formalin inactivated VEEV vaccine,
C84, for example, provides only a limited protection from aerosol
challenge. It induces a limited neutralisation antibody response
and requires regularly and periodic boosters [26]. Therefore,
antiviral therapies effective in prophylaxis and treatment of VEEV
infection are required and the administration of virus neutralising
or otherwise inactivating antibodies could serve as a reasonable
alternative to vaccination. In addition, the application of murine
antibodies to humans is often critical and limited due to their high
immunogenicity, risk of serum sickness and anaphylactic shock.
Therefore, human or humanised antibodies as well as antibodies
from non-human primates like macaque could offer an alternative
for passive protection or therapeutic treatment of VEE.
In this work, we describe the isolation of the anti-VEEV single
scFv ToR67-3B4 using antibody phage display from a non-human
primate (NHP) antibody gene library. We describe the immuno-
logical and biochemical characterisation of its cognate Fc-fusion
and investigate its in vivo stability as well as its in vivo and in vitro
inactivation potential in BALB/c mice.
Materials and Methods
Ethical Statement
Macaque care. The animal experiment was approved by the
ethics committee for animal experimentation of IRBA-CRSSA
(Institut de Recherche Biome ´dicale des Arme ´es - Centre de
Recherche du Service de Sante ´ des Arme ´es). The ethics committee
number for the VEE macaque immunisation was 2008/03.1. The
immunisation with inactivated virus particles was performed
according to the governmental french ethical guidelines: ‘‘Partie
reglementaire du livre II du code rural (Titre I, chapitre IV,
section 5, sous section 3: expe ´rimentation sur l’animal)’’, ‘‘De ´cret
87–848 du 19-10/1987 relatif aux expe ´riences pratique ´es sur les
animaux verte ´bre ´s, modifie ´ par le de ´cret 2001/464 du 29/05/
2001’’, ‘‘Arre ˆte ´ du 29 octobre 1990 relatif aux conditions de
l’expe ´rimentation animale pour le ministe `re de la de ´fense’’ and
‘‘Instruction 844/DEF/DCSSA/AST/VET du 9 avril 1991
relative aux conditions de re ´alisation de l’expe ´rimentation
animale’’. Animal care procedures were in compliance with the
regulations detailed under the Animal Welfare Act [33] and in the
Guide for the Care and use of Laboratory Animals [34]. Animals
were kept under stable temperature (2262uC) and relative
humidity (50%) conditions, with 12 hours of artificial lighting
per day. Their cages were individual (6 per room) and each had a
perch. Animals were fed twice a day, once with dried food, once
with fresh fruits and vegetables, and water was provided
concurrently. The food intake and general behaviour were
observed during feeding by animal technicians, who were able
to access a veterinarian if needed. Systematic veterinary visits to
each NHP-room were conducted twice a week. General anesthesia
was administered prior to any blood or bone marrow collection.
Additionally, subsequent analgesics were administered in the
following days by animal technicians if pain was suspected,
according to the observations of animal behaviour.
Mice infection. The use of mice for passive protection studies
for research purposes complied with UK guidelines. Animal
protocols adhered to the Animals (Scientific Procedures) Act 1986,
and protocols were approved by the UK Home Office. The study
was performed under project licence 30/2425 and was approved
internally by a Defence Science and Technology Laboratory (Dstl)
ethical review process.
Cell culture and virus production. All viruses used in this
study represent models for biowarfare agent relevant Alphavirus
species and are either part of the strain collection of the Armed
Forces Scientific Institute for Protection Technologies – NBC
Protection (WIS) or are part of the strain collection of the Defence
Science and Technology Laboratory, Porton Down, UK. Strains
of VEEV from subtypes IA/B (Trinidad donkey; TrD), IC (P676),
ID (3880), IE (Mena II), IF (78V), Everglades virus (formerly
subtype II, strain Fe37c), Mucambo virus (formerly subtype IIIA,
strain BeAn8), Pixuna virus (formerly subtype IV), Cabassou virus
(formerly subtype V, strain CaAr508) and Rio Negro virus
(formerly subtype VI, strain AG80) were kindly supplied by Dr.
R.E. Shope (University of Texas Medical Branch, USA). Eastern
equine encephalitis virus (EEEV) strain H178/99 and Western
equine encephalitis virus (WEEV) strain H160/99 used in this
study were received from the National Collection of Pathogenic
Viruses (NCPV), UK.
Alphaviruses were either propagated in Baby Hamster Kidney
(BHK), Vero-B4 (African green monkey kidney) or L929 (murine
fibroblast) cells at 37uC and 5% CO2 in a biosafety 3 facility
according to standard procedures as described [18,35–37]. The
cell lines were obtained from the DSMZ-ACC 33 (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH),
Braunschweig, Germany or the European Collection of Animal
Cell Cultures, Porton Down, Salisbury, UK.
All viruses were harvested from infected cells when 50–75% of
the cell monolayer showed evidence of viral cytopathic effect
(CPE). Virus titers were either determined by the 50% tissue
culture infective dose (TCID50/mL) method according to Spear-
man and Kaerber or plaque assay [38–40]. Titers typically ranged
from 1.0610
7 to 1.2610
10 TCID50/ml.
Purification of Alphaviruses. Virus containing superna-
tants from infected Vero cells were either purified by affinity
chromatography on Matrex Cellufine Sulfate Medium
TM (Virus
Recovery System, VRS, Chisso America Inc., NY, USA) or by
isopycnic density gradient centrifugation as described below.
Matrex Cellufine Sulfate Medium
TM (VRS) is a cellulose bead
medium functionalised with a low concentration of sulfate esters
that operates similar to a cation-exchange resin and has a high
affinity for enveloped viruses. It selectively adsorbs complete virus
particles as well as viral coats according to their charge. Briefly,
50 mL resin was equilibrated with adsorption buffer (0.01 M
phosphate buffer, pH 7.5). Up to 200 mL of virus containing
prefiltered cell culture supernatant was loaded onto the column
which then was washed twice with 0.01 M phosphate buffer,
pH 7.5. Elution of virus particles was performed with 1 M NaCl.
Purification of virus particles was carried out in two steps.
Prepurification was performed by the sucrose cushion ultracentri-
fugation method (20% sucrose cushion), which causes low
mechanical stress and allows the concentration and collection of
morphologically intact particles after centrifugation at 112,0006g
for 2 to 3 hours. The pellet was resuspended in 0.5 to 1 mL
phosphate buffered saline (PBS) and further purified by isopycnic
density gradient centrifugation (20 to 60% sucrose) for 18 hours at
A VEEV Specific Human-Like Antibody Fragment(scFv)
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stored at 280uC until subjected to further analysis.
Inactivation of Alphaviruses. Inactivation of all viral
antigens was performed with a final concentration of 0.1% ß-
propionolactone (ß-PL, Sigma-Aldrich, Taufkirchen, Germany).
Immediately before use a 10% ß-PL solution was prepared and
0.1 ml of this dilution was incubated with 5 ml of virus containing
cell culture supernatant (pH 8 to 8.5) for 1 h at 4uC and 4 hours at
37uC with constant stirring. After 2 and 4 hours the pH of the cell
culture supernatant was controlled and adjusted if necessary. In
order to achieve a complete hydrolysis of remaining ß-PL after the
inactivation the supernatant was kept at 4uC for another 12 to
18 hours. After low speed centrifugation of the sample for 30 min
at 10006 g the viral inactivation was verified by inoculation of
Vero cells and monitoring for cytopathic effects (CPE) for 3 to 5
days.
Animal immunisation. A male cynomolgus macaque (Ma-
caca fascicularis) was immunised by intramuscular injection with
100 ml of the commercially available veterinary vaccine Fluvac
Innovator Triple EFT plus EHV (Fort Dodge Animal Health,
USA). This all-around vaccine is normally applied to horses in
order to protect them from equine encephalitis caused by EEE,
WEE and VEE viruses. In addition, the vaccine contains
inactivated rhino- and influenza viruses as well as tetanus toxoid
to protect horses from equine rhinopneumonitis, influenza and
tetanus.
days after this first immunisation the macaque was immunised
with 100 ml of VRS purified ß-PL inactivated VEEV TC83
(TCID50/ml of 2610
10) in combination with complete Freund’s
adjuvant. Subsequently, 5 additional antigen injections of 100 ml
were performed after 65, 90,150, 210 and 350 days with
incomplete Freund’s adjuvant. Ten days after the final antigen
injection the immune library was generated.
After each boost immune sera were gathered, inactivated for
20 min at 56uC and tested for VEEV specific antibody titer by
ELISA. For this purpose either VRS-purified culture supernatants
from VEEV TC83 infected Vero cells or uninfected cells were
immobilised on 96 well-microtiter plates (Maxisorp
TM, Nunc,
Wiesbaden, Germany). For the determination of VEEV specific
antibody titers serial dilutions of pre-immune-serum (PI 543) and
immune sera (S543) were applied. Specifically bound antibodies
were detected by incubation with rabbit anti-monkey IgG
conjugated to horseradish peroxidase (1:10.000, Sigma-Aldrich,
Taufkirchen, Germany) for 30 minutes at room temperature.
Staining was performed with 3-39, 5-59 -tetramethylbenzidine
(TMB, Serva, Heidelberg, Germany) and stopped with 2 M
sulphuric acid after 10 minutes. Absorbance was measured at
450 nm.
Library construction and screening of recombinant
antibodies. Lymphocytes of the macaque bone marrow were
sampled after 6 boosts and subjected to RNA preparation by using
Tri Reagent (Molecular Research Center Inc, Cincinnati, USA).
The isolated RNA was reverse transcribed to cDNA and diverse
combinations of forward and reverse primers were used to amplify
DNA, coding for the variable regions of antibodies, VLk and VH
[41]. In order to obtain the cognate sublibraries, the PCR
fragments were subcloned into the pGemT vector (Promega,
Madison, Wisconsin) as described [41–45]. For the phage-
displayed library the precloned VH and VL repertoire was
reamplified and specific restriction sites were inserted by PCR
[42]. For the construction of the library the reamplified VH and
VL genes were subcloned into the phagemid pHAL14 in two
successive ligation steps. The VH PCR products were subcloned
into pHAL14 as HindIII-NcoI fragment, the VL PCR products
were inserted as NotI-MluI fragment.
The phagemid pHAL14 was chosen as library vector because it
allows phage display and the production of soluble antibody
fragments without the necessity of recloning. pHAL14 is a high-
copy plasmid and contains the scFv under the control of the lacI
promoter/operator region which is inducible by IPTG. A His- and
c-Myc-tag are encoded at the C-terminus in frame with the scFv
and allow the straightforward purification of the recombinant
antibody [45].
All cloning and ligation procedures necessary for the library
construction were performed in E. coli XL1-Blue MRF’ (Strata-
gene, Amsterdam, The Netherlands) according to Sambrook et al.,
1989 [46]. For DNA plasmid and PCR product purification the
commercial Plasmid Mini Kit and QIAquick PCR Purification Kit
from QIAGEN, Hilden, Germany, were used.
The library was packaged by using Hyperphage [47,48].
Therefore, 1 ml of the antibody gene library stock was grown to
an OD600 nm of 0.4 to 0.5 and about 1.25610
10 E. coli XL1-Blue
MRF’ transformants were infected with 2.5610
11 Hyperphage.
E. coli cells and Hyperphage were incubated for 30 min at 37uC
without shaking, followed by a further incubation for 30 min with
shaking at 250 rpm. The infected cells were harvested by
centrifugation and transferred to glucose-free TY-medium con-
taining 100 mg/ml ampicillin and 50 mg/ml kanamycin in order to
repress the lac promoter of pHAL14 and allow the expression of
the scFv::pIII fusions. After incubation overnight at 250 rpm and
30uC bacteria were removed by centrifugation and phage particles
in the culture supernatant were precipitated as previously
described [49]. The precipitated and packaged antibody phage
library was then resuspended, titered and stored at 4uC until used
for the panning and screening [49].
Surface presentation onto phage of the library was examined by
SDS-PAGE, Western blotting and anti-pIII immuno-staining as
described [50].
The process for the selection of specific scFv from a phage-
displayed library is referred to as ‘‘panning,’’and, in principle,
involves the selection of Abs on the basis of their affinity.
The panning of VEEV specific scFv was performed on VRS
purified VEEV presented by specifc mAbs coated onto 96 well
microtitre plates (Maxisorb, Nunc, Wiesbaden, Germany) with
minor modifications according to [12].
The panning and amplification of specifically bound phage was
repeated three times before proceeding with postpanning analysis
and each panning included a preselection and selection step. In
order to remove unspecific binders, the library was preincubated
in parallel with non-infected Vero cells and a nonspecific murine
IgG. Therefore, 100 ml of the phage library was incubated for 1 h
at room temperature (RT) onto a mixture of coated and
concentrated VRS supernatant from non-infected Vero cells plus
1% BSA (bovine serum albumin) in PBST (PBS plus 0.01%
Tween 20) containing 10 mg/ml of the murine IgG D1-4G2-4-15
[51].Washing and reamplification of specifically bound phage was
performed as described [12].
Sequencing and sequence analysis. Sequencing was per-
formed by GATC Inc. (Konstanz, Germany) using the oligonu-
cleotide primer MHLacZ-Pro_f (59 ggctcgtatgttgtgtgg 39). The
antibody gene fragments were analysed by using VBASE2 (http://
www.vbase2.org) and Kabat’s database of sequences of immuno-
logical interest (www.bioinf.org.uk) as previously described
[45,52].
Construction of stable eukaryotic tranfectants,
expression and production of scFv-Fc ToR67-3B4. VEEV
specific scFv gene fragments were subcloned from the immune
A VEEV Specific Human-Like Antibody Fragment(scFv)
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pCMV2.5-hIgG1-Fc by using the restriction sites NcoI and NotI
[49]. The mammalian expression vector allows the expression of
scFvs in frame with the human IgG1 gene. The fusion is under the
control of the CMV promoter. Moreover, the vector contains
besides the bla-gene a neomycin phosphotransferase (Neo)
expression cassette for antibiotic selection with G418.
For the stable production of VEEV specific scFv-Fc fusion
proteins, Chinese hamster ovary K1 cells (CHO-K1), from the
American Type Culture Collection, (ATCC, Rockwell, MD,
No. CCL61) were transfected by using 80 ml PolyfectH (Qiagen
GmbH, Hilden, Germany) plus 4 to 5 mg of plasmid DNA. Stable
clones were selected for resistance to the aminoglycoside antibiotic
Geneticin (G418). For this purpose CHO-K1 cells were cultivated
to 60% to 80% confluence overnight in 1000 mm
2 Petri dishes
(Nunc, Vienna, Austria) in non-selective Dulbecco’s Modified
Eagle’s Medium (DMEM/HAM’s F-12), a nutrient mixture
supplemented with L-glutamine and sodium bicarbonate, con-
taining 10% (v/v) fetal calf serum (FCS) and 0.1% (w/v) penicillin
and 0.1% (w/v) streptomycin (PAA, Parsing, Austria) at 37uCi n
4% CO2 atmosphere. In order to support the DNA-lipid complex
formation, plasmid DNA and PolyfectH were preincubated in
serum- and antibiotic-free medium for 10 minutes at room
temperature prior to transfection. While the lipid-DNA complex
formation took place, CHO-K1 cells were washed with PBS.
Afterwards, 7 ml of medium with FCS and penicillin/streptomy-
cin was added to the complex. The whole mixture was then
immediately added to the washed cells by gently swirling. Cells
were incubated for 3 h with the transfection complex. Subse-
quently the medium was removed and replaced with fresh non-
selective DMEM/HAM’s F-12 containing 10% (v/v) FCS and
0.1% (w/v) penicillin/streptomycin before the plates were
incubated overnight at 37uCi n4 %C O 2. A further medium
change was performed one day after the transfection. The
transfected cells were trypsinised and re-sown 1:20 or 1:50 in
new Petri dishes on selective medium, containing additionaly
700 mg/ml G418. Medium change was performed every 3 to 4
days and first stable and G418-resistant clones were visible about 3
weeks after transfection. Four and five weeks after transfection
single clones were isolated and cultivated onto 24 well plates
(Nunc, Vienna, Austria). Since the productivity of individual
clones varies, we tested the supernatant of 48 clones for VEEV-
specific scFv-fusion production in ELISAs as described. Finally,
three of the best expressing CHO-K1-clones were cultivated as
suspension culture in a miniPerm bioreactor (Sarstedt, Nu ¨m-
brecht, Germany) in DMEM/HAM’s F-12 containing 10% (v/v)
(FCS), 1% (w/v) penicillin/streptomycin and 700 mg/ml G418 at
37uCi n4 %C O 2. The culture supernatant was harvested twice a
week and replaced by fresh medium. Purification of recombinant
fusion proteins was done by immunoaffinity chromatography on
goat anti-human (GAH) sepharose.
Biotinylation of mAbs and scFv-Fc fusions. One to two
mg of mAb or scFv-Fc was dissolved in sodium bicarbonate buffer,
pH 8.5, and incubated with an aliquot of the biotin N-
hydroxysuccinimide ester (long arm, water soluble) from Vector
laboratories, CA, USA, equal to 1/10 the weight of the protein to
be labeled. The mixture was incubated for 2 hours at room
temperature. In order to stop the reaction 10 mg of glycine was
added and unreacted biotin was removed by gel filtration with PD-
10 desalting columns containing Sephadex G25 (GE Healthcare,
USA) according to the suppliers’ protocol.
Enzyme-linked immunoassays (ELISAs) with scFv-Fc
fusions
Indirect ELISA. Sucrose density gradient-purified antigen
from strains TrD, P676, 3880, Mena II, 78 V, Fe37c, BeAn8,
Pixuna, CaAr508 and AG80 (subtypes IA/B, IC, ID, IE, IF,
formerly subtypes II IIIA, IV, V and VI) were coated on 96-well
Maxisorp
TM microtiter plates purchased from Nunc, Wiesbaden,
Germany. The viral protein concentration was determined by
SDS-PAGE and scanning dosimetry, dilutions were performed in
50 mM bicarbonate buffer pH 8.5. After blocking with PBS
containing 1% (w/v) skimmed milk powder (Sigma-Aldrich, UK)
plus 0.1% (v/v) Tween 20 detection of VEEV strains was
performed with different log10 dilutions of scFv-Fc ToR67-3B4
for 2 hours at room temperature (RT). The starting concentration
was 1 mg/ml. Subsequently the microwell plates were washed with
PBS-T and the presence of bound antibody was detected by using
peroxidase-conjugated goat-anti-human IgG (1:4.000, AbD Ser-
otec, UK) as secondary antibody. TMB-substrate (Sigma-Aldrich,
UK) was used as chromogenic substrate, absorbance was
measured at 450 nm.
Direct Sandwich ELISA. All sandwich ELISAs were per-
formed in 96 microwell plates (Maxisorp
TM, Nunc, Wiesbaden,
Germany) that were either coated with 3 mg/ml antibody or scFv-
Fc by incubation for 2 h at 37uC or overnight at 4uC. For the
detection of VEEV we used either the monoclonal antibody (mAb)
VEE-WIS1 or a mixture of mAbs VEE-WIS1, SFV3/4 and SFV
12/2 as capture antibodies [9,16–19]. MAb VEE-WIS1 (E1-
specific) regognises specifically VEEV of subtype IA/B, while the
antibody mixture binds Old world as well as New world
Alphaviruses. In order to capture WEEV specifically mAb SVF
12/2 was applied. The ELISA to detect EEE virus was done on
plates coated with a mixture of mAbs SFV 8/6 (E1-specific),
SFV3/4 and SFV 12/2 [9,16–19]. Subsequently antibody coated
microtiter plates were washed and blocked with 1% FCS in PBS-T
during 1 h at room temperature. After further washes, wells were
additionally overlayed with liquid plate sealer (Candor Bioscience
GmbH, Wangen, Germany), stored at 4uC and used for ELISA
studies within three to six weeks. Samples with virus were
incubated for 2 h at room temperature on precoated microwell
plates and afterwards extensively washed. Bound viruses were
detected by using biotinylated scFv-Fcs or mAbs in appropriate
dilutions (1:500, 1:2000 or 1:5000) and incubation for 1 h at 37uC.
After three further washes the conjugate Streptavidin-horseradish
peroxidase (PSA, GE Healthcare, USA) was applied to the wells in
a 1: 6000 dilution and plates were incubated for 30 min at RT
with agitation. Bound biotinylated mAbs and fusions were
detected by using TMB staining (commercial solution from Serva,
Heidelberg, Germany) that was stopped with 2 M sulphuric acid
after 10 minutes. Absorbance was measured at 450 nm.
Immunoblot analysis. ScFv-Fc fusion proteins and several
monoclonal antibodies as positive controls were used to detect
VEEV specific envelope proteins.
Therefore, purified VEEV particles were disrupted either by
incubation for 20 minutes at 56uC or 5 minutes at 95uCi n
Laemmli sample buffer [53] containing either no or 1 mM DTT.
The viral proteins were separated by 15% SDS-PAGE and blotted
onto a nitrocellulose membrane (Protran, BA85, Sigma-Aldrich,
Taufkirchen, Germany). The membrane was blocked with PBS
plus 1% Casein, pH7.4 (Thermo Fisher Scientific GmbH,
Dreieich, Germany) for 1 h at RT. For the detection of virus-
specific proteins, the membrane was incubated with either
biotinylated scFv-Fc (Tor67-3B4: 1:5000) fusions or mAbs (SFV
8/6: E1-specific mAb, 1:10.000; WIS-VEE1: E1-specific mAb,
1:1.000; 1A3B7: E2-specific mAb, 1:1.000) for 1.5 h at RT in the
A VEEV Specific Human-Like Antibody Fragment(scFv)
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with the conjugate streptavidin-alkaline phosphatase (1:1000, GE
Healthcare, Munic, Germany) for 30 min. Staining and visualisa-
tion of specific proteins was performed with 5-Brom-4-Chlor-3-
Indolyl-Phosphat/Nitro Tetrazolium Blue Chloride (NBT-BCIP,
Thermo Fisher Scientific GmbH, Dreieich, Germany) according
to standard procedures.
Immunohistochemistry. Vero cells (100 mlo f2 610
5 cells/
ml) were grown in 96-well microtiter plates for 24 h and
subsequently infected with serial log10 dilutions of either VEEV
TC83 or TrD. Non-infected Vero cells served as negative control.
Specific staining of VEEV infected cells was performed with
biotinylated scFv-Fc ToR67-3B4 and mAb SFV 8/6 as positive
control. In detail, one day post infection the infected cells were
fixed with 3% formalin in PBS for 3 h at 4uC. Afterwards the fixed
samples were incubated with their cognate antibodies in either a
1:5000 or 1:10.000 dilution in PBSF-T (PBST plus 1% FCS) for
1 h in a humid chamber at 37uC. After 3 consecutive washes in
PBS-T the fixed cells were incubated for 30 min with the
conjugate streptavidin - horseradish peroxidase (PSA, GE
Healthcare, USA) diluted 1:6000 in PBS-FT. After further
extensive washing and in order to visualise infected cells
microscopically, the samples were incubated with the precipitating
colorimetric peroxidase substrate TMB (KPL, Germany) for
10 minutes. Staining was stopped by rinsing the plates with
Millipore-purified water.
Neutralisation tests
Neutralising peroxidase-linked antibody (NPLA)
assay. The NPLA assay for scFv-Fc fusions and complete IgG
antibodies was done according to the technique of Jensen [54]
with several modifications. All assays were performed in 96 well
microwell plates and Vero cells were used as host for infection.
Fifty ml of two-fold dilutions of scFv-Fc fusions or mAbs (starting
concentration between 0.5 to 1.0 mg/ml) were incubated with an
equal volume of VEE virus strains TC-83, TrD or Fe3-7c with a
TCID50/ml of 5610
4 for 2 hours at 37uC in 96-well plates.
Following this incubation, 100 ml of freshly trypsinised Vero cells
at a concentration of 4610
5 cells/ml were transferred to the
antibody virus mixture.
As positive control for infection, virus samples not preincubated
with any antibody as well as virus samples preincubated with
VEEV specific antibodies that do not display any neutralising
activity like mAb WIS VEE1 were used. Moreover, virus samples
preincubated with mAb SFV 8/6 and 1A3B-7, both antibodies
with known neutralizing capacity ([55] and Hu ¨lseweh, personal
communication) were applied as a positive control and non-
infected Vero cells served as negative control. Twenty to twenty-
four hours post infection all cell monolayers were fixed with 3%
formalin in PBS for 3 h at 4uC and infection of cells was
demonstrated by specific immunostaining of viral antigens. After
washing with PBS-T, the monolayers were overlaid with 100 mlo f
a 1:5000 dilution of the VEEV-specific biotinylated mAb SFV 8/6
and incubated for 2 h at RT. Bound biotinylated mAbs were
detected by using the streptavidin HRP conjugate (GE Healthcare,
USA, 1:6.000) and visualisation was performed with precipitating
TMB as substrate. The staining reaction was stopped by adding
100 ml of 1 M sulphuric acid and absorbance was measured at
450 nm in a microwell plate reader. The absorbance values were
correlated to relative infectious activity. Thereby absorption at
450 nm (OD450 nm) values of the positive control, namely Vero
B4 cells infected with VEEV, were set as 100% infectivity. A
reduction equal or greater than 50% in A450nm in the wells was
considered as indicative for neutralisation.
Plaque reduction Assay. The ability of scFv-Fc ToR67-3B4
(25 mg) to neutralise virus infectivity was determined by mixing the
construct with VEEV strains TrD, Fe37c or BeAn8 (approxi-
mately 100 pfu) and incubating at 4uC overnight. Residual
infectious virus was estimated by a standard plaque assay in
L929 cells as described [37].
Determination of the in vivo half-life of scFv-Fc ToR67-
3B4. Sera were harvested from the marginal tail veins of three
BALB/c mice (6–8 weeks old; Charles River Laboratories, UK).
Five days later, 100 mg scFv-Fc ToR67-3B4 were injected by the
intraperitoneal route. Serum samples were collected 8 h, 1 d, 3 d,
5 d, 10 d, 15 d and 25 d post-administration. The concentration
of scFv-Fc ToR67-3B4 in sera was determined by ELISA using
sucrose density gradient-purified b-propiolactone inactivated
antigen of VEEV strain TC-83. Antibody concentrations were
estimated by comparison of the absorbance values generated by
diluted serum samples with a standard curve prepared with scFv-
Fc ToR67-3B4.
Statistical methods. Statistical analysis was performed using
GraphPad Prism software (http://www.graphpad.com). To deter-
mine the half-life of scFv-Fc ToR-3B4 in vivo, a linear regression
model was fitted to the log transformed data to estimate the rate of
change over time. A change of 0.30 units on the log scale equates
to a 50% reduction of the data on the original scale. This value is
divided by the estimated model slope to obtain the half-life.
Passive protection studies. BALB/c mice, 6–8 weeks old,
were used for all passive antibody protection studies. Mice were
challenged by the airborne route with 100LD50 strain TrD
[56,57]. The LD50s for strains Mena II, Fe37c and Mucambo
virus have not been determined. However, titres were used in the
collision nebuliser that have reliably achieved 100% mortality in
previous experiments [36,37]. Afterwards mice remained either
untreated or were injected intraperitoneally with 100 mg scFv-Fc
ToR67-3B4, human IgG (Sigma-Aldrich, Taufkirchen, Germany)
or control construct (anti-WEEV). Mice received just one injection
at a single time-point (6, 24, 48 or 72 h) post-challenge and were
monitored for clinical signs of infection (piloerection, hunching,
inactivity, excitability and paralysis) twice daily by an observer
who was unaware of the treatment allocations. Animals were
scored according to the severity of the clinical signs and were
humanely culled as appropriate [58]. These experiments therefore
record the occurrence of severe disease rather than mortality.
Even though it is rare for animals infected with virulent VEEV
and showing signs of severe illness to survive, our use of humane
endpoints should be considered when interpreting any virus dose
expressed here as 50% lethal doses (LD50). In one experiment, sera
were harvested by cardiac puncture from mice that were alive
fourteen days post-challenge. Samples were assayed for VEEV-
specific antibodies using sucrose density gradient-purified b-
propiolactone-inactivated antigen from strain TC-83.
Results
Construction of the macaque immune library and
screening of VEEV specific recombinant antibodies
In order to generate antibody fragments reactive to members of
the VEE virus sero-complex we constructed a VEEV specific scFv
antibody gene library 360 days post the sixth immunisation of a
non-human primate (Macaca fascicularis) with ß-PL inactivated
VEEV TC83. Donor sera ELISA titers to VEEV TC83 rose
continuously in the course of immunisation and showed a clear
VEEV-specific binding in comparison to the pre-immune serum.
After six VEEV TC83 injections, the specific serum antibody titer
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tested positive for neutralisation of VEEV TC83 (data not shown).
For the macaque immune library, total RNA was isolated from
lymphocytes of the bone marrow and reverse transcribed to
cDNA. After PCR amplification and precloning of the antibody
fragments for VH and VLk the final phage displayed library was
established in the phagemid pHAL14, a vector that allows phage
display and the production of soluble antibody fragments without
the necessity of recloning. [49]. The library quality was analysed
by colony PCR. About 90% of the 1.6610
7 independent clones
contained a full size scFv insert. In order to improve the antibody
display efficiency the library was packaged by Hyperphage, a
substitute for M13KO7 helper phage. Correct surface presenta-
tion onto phage was examined by SDS-PAGE, Western blotting
and anti-pIII immuno-staining as described [50].
All pannings were performed in a biosafety level 3 laboratory by
using the VEEV vaccine strain, TC83, as a medically important
and epizootic antigen.
The phage display antibody gene library was subjected to 3
rounds of panning and representative phage clones were assessed
for their ability to bind to VEEV TC83 immobilized onto 96
microwell plates. The enrichment of false-positive antibody phage
particles was excluded by preincubation of the library with the
supernatant of non-infected Vero cells. Non-specific binding of
scFv phage to the VEEV-specific capture antibodies mAb 8747
and mAb VEE-WIS1 was reduced by preabsorption of the library.
Moreover, these two antibodies were added for competitive
binding during the panning procedure.
In total, 322 monoclonal soluble scFvs produced from E. coli
clones were analysed by ELISA on immobilized inactivated VEEV
particles. Twenty-four monoclonal ELISA positive binders were
identified. Their specific antigen binding was confirmed on
infectious as well as on ß-PL inactivated VEEV of subtype IA/B.
Sequencing and nucleic acid analysis of scFv clones
The DNA fragments of 24 positive monoclonal binders were
sequenced in order to identify unique binders and to define the
germline gene family and the amino-acid subgroups of the heavy
(VH) and light (VL) chain variable regions. However, three rounds
of panning yielded only one unique VEEV-specific clone that
predominated the resulting antibody panel. All binders were
identical in their VH and VL sequences. Thereafter, further
analysis was exclusively performed with the binder ToR67-3B4.
The alignment of the amino acid sequence of ToR67-3B4 to
VBASE2, the integrative database of germ-line variable genes
from IgG loci of human and mouse, showed the highest similarity
to the human IGHV4-59*01 and IGKV2-30*01. Furthermore, we
calculated the G-score of the antibody’s variable (V) regions since
macaque antibodies have been suggested to have extremely
human-like character [59], a property that could be especially
beneficial for a therapeutical antibody. The VH region of ToR67-
3B4 had a G-score of 0.707 thus meaning that it has the same level
of similarity as 24% VH sequences present in Kabat’s database. If
the human VH sequences present in Kabat’s database are
regarded as representative of human VH sequences, this result
may be summarized as ‘‘the VH region of ToR67-3B4 is as human
as 24% of human VH regions’’. The VL chain displayed a G-score
of 21.505, indicating that it is ‘‘as human as’’ 7% of human
sequences present in the Kabat database.
Enhancing ToR67-3B4 binding properties by subcloning
the scFv in an eucaryotic expression vector
By one step subcloning, the scFv ToR67-3B4 was inserted as a
NcoI-NotI fragment into the mammalian expression vector
pCMX2.5-hIgG1-Fc-XP, that allowed the fusion of scFv antibody
coding regions to the gene fragment encoding the human IgG1 Fc
part (hinge-CH2-CH3) and enabled the stable expression of
homodimeric and bivalent scFv-Fc fusion proteins in CHO-K1
cells. Moreover, the IgG1 Fc part allowed routinely high affinity
purification with goat anti-human antibodies coupled to sephar-
ose. The fusion of a scFv to a Fc part mediates enhanced in vitro
protein stability, could prolong serum half-life and mediates IgG
effector functions if necessary [60].
Reactivity of scFv-Fc fusion ToR-3B4 to different VEEV
strains and other Alphaviruses
The ability of scFv-Fc ToR67-3B4 to recognise different
subtypes of VEEV strains was evaluated by an indirect ELISA.
For this purpose, sucrose density gradient-purified antigens from
strains TrD, P676, 3880, Mena II, 78 V, Fe37c, BeAn8, Pixuna,
CaAr508 and AG80 (subtypes IA/B, IC, ID, IE, IF, formerly
subtypes II, IIIA, IV, V and VI respectively) were prepared and
coated in comparable amounts onto 96-well microtiter plates. At a
concentration of 1 mg/ml, scFv-Fc ToR67-3B4 reacted with
multiple VEEV subspecies in ELISA with a strong affinity to all
subtype 1 varieties (IA/B, IC, ID, IE, IF) but also recognized
Everglades, Mucambo, Pixuna, Cabassou and Rio Negro virus
(formerly subtypes II, IIIA, IV, V and VI, see Figure 2A). Diluting
scFv-Fc TOR-3B4 proved that the recombinant antibody reacted
equally well with all the VEEV strains to which it was able to bind
strongly.
Moreover, the ability of scFv-Fc ToR67-3B4 to detect different
Alphavirus species was tested by a direct sandwich ELISA, using
scFv-Fc ToR67-3B4 either as detection (Figure 2B) or capture
antibody (Figure 2C). As illustrated in figure 2B scFv-Fc ToR67-
3B4 displayed only marginal cross-reactivity to other Alphavirus
species except for EEEV if applied for detection. The recombinant
antibody can be combined with the capture antibody mAb VEE
WIS1 for the highly specific detection of VEEV. At least a
TCID50/ml of 10
6 was manifested as detection limit in a sandwich
ELISA for strain TC83 (IA/B).
Figure 1. Titration of monkey sera after the final boost. Either
VRS-purified culture supernatants from VEEV TC83 infected Vero cell or
uninfected cells (negative control) were immobilised on 96well-
microtiter plates. For the detection of a VEEV specific antibody titer,
serial dilutions of pre-immune serum (PI 543) and immune serum (S543)
after the sixth boost were applied. Bound antibodies were detected by
rabbit anti-monkey IgG conjugated to horseradish peroxidase and
staining with TMB.
doi:10.1371/journal.pone.0037242.g001
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antibody in combination with an Alphavirus-specific detection mix
the recombinant antibody displayed a considerably broader cross-
reactivity. As illustrated in figure 2C, scFv-Fc ToR67-3B4 bound
additionally to VEEV, EEEV, CHIKV and SFV. It also showed a
low relative binding efficiency to SINV and WEEV.
Immunohistochemistry and Immunoblot analysis
ScFv-Fc ToR67-3B4 can be used for immunohistochemistry of
VEEV infected cells and Western blot analysis of VEEV proteins
(Figure 3). As expected, Vero cells infected with VEEV TrD
displayed a strong perinuclear signal 1 day post infection when
stained with either scFv-Fc ToR67-3B4 or the well established
mAb SFV 8/6 [11,16,17]. Similar results were obtained for Vero
cells infected with the vaccine derivative TC83 (data not shown)
while non-infected cells showed no specific binding.
The glycoprotein envelope of Alphaviruses is made up of two
proteins, E1 and E2. While E1 is responsible for the fusion process
with the host cell membrane, E2 is responsible for cell receptor
binding. In order to examine which VEEV specific structural
glycoprotein is recognised by scFv-Fc ToR67-3B4 we electropho-
retically separated purified virus samples after disintegration in a
15% PAA gel under non-reducing conditions. The proteins were
blotted onto a nitrocellulose membrane and stained as described.
The E1 specific antibodies mAb SFV 8/6 [10,11] and mAb VEE
WIS1 as well as the E2-specific antibody mAb 1A3B7 served as
positive control and detected proteins of about 47 kDa and
52 KDa. The recombinant antibody recognized specifically the
Alphavirus E1 glycoprotein of about 47 kDa (Figure 3A). If the
virus sample was additionally reduced by adding DTT prior to
SDS-PAGE, no specific binding was observed.
Neutralisation activity of scFv-Fc fusion proteins against
multiple VEEV strains
Heterodimers of the E1 and E2 structural proteins occur on the
surface of VEEV and antibody reactivity to either glycoprotein
may result in protection against disease in vitro and in vivo
[36,55,61–63].
For this purpose the ability of scFv-Fc ToR67-3B4 to neutralise
virus infectivity in vitro was assessed for different VEEV strains in 2
to 3 independent experiments. Serial dilutions of scFv-Fc ToR67
3B4 were mixed with a TCID50/ml of 5610
4 of VEEV of subtype
IA/B and II. The virus antibody mixtures were incubated at 37uC
for 2 hours and subsequently subjected to cell culture infection.
Residual infectious activity of virus was estimated by specific
immunostaining one day post infection with VEEV-specific
antibodies. Absorbance (OD450 nm) values obtained with virus
samples not preincubated with any antibody served as the positive
control and were set as 100% infectivity, non-infected Vero cells
were used as the negative control.
A reduction in absorbance at 450 nm equal to or greater than
50% in wells was considered as indicative of neutralization. In
Figure 2. Reactivity of scFv-Fc ToR 67- 3B4 to Alphavirus
subspecies and species. Panel 2A shows the antigen binding
efficiency of ToR67-3B4 on different immobilised VEEV subtypes at a
concentration of 1 mg/ml, n=1 for all data points. Panel 2B illustrates
the cross-reactivity of scFv-Fc ToR67-3B4 to a range of Alphavirus
species analysed by a sandwich ELISA. Antigens were captured by an
anti-Alphavirus mAb mix, specifically bound virus was detected by
biotinylated scFv-Fc ToR67-3B4 (1:5000). The insert in the upper right
corner of the bar chart shows the positive control and demonstrates
that all Alphaviruses except SINV are specifically captured by the
antibody mixture. Detection of virus was performed with the same
biotinylated anti- Alphavirus mAb mix. All viral antigens were applied
with a TCID50/ml of 5610
7 to 10
8. Culture supernatant of non-infected
Vero cells was used as negative control. The mean values of two ELISAs
from two independent experiments are shown. In panel 2C scFv-Fc
ToR67-3B4 was applied as capture antibody in combination with the
cognate Alphavirus-specific antibody mixture for group-specific detec-
tion. Viral antigens were applied with a TCID50/ml of 5610
7 to 10
8.
Culture supernatant of non-infected Vero was used as negative control.
The mean values of two ELISAs from three independent experiments
are shown. Panel 2D shows the detection limit for vaccine strain TC83
(subtype IA/B) using capture antibody mAb VEE WIS1 paired with
biotinylated scFv-Fc ToR67-3B4 detector antibody (1:5000). Virus was
titrated in 2-fold dilutions. The data represents 2 separate experiments
with 3 replicates of each concentration. Abbreviations used in this
legend are BHK: Baby hamster kidney cells, VEEV: Venezuelean equine
encephalitis virus, WEEV: Western equine encephalitis virus, EEEV:
Eastern equine encephalitis virus, CHIKV: Chikungunya virus, SINV:
Sindbis virus and SFV: Semliki Forest virus.
doi:10.1371/journal.pone.0037242.g002
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bodies with known neutralising activity, like mAb SFV 8/6 or
mAb1A3B7, were used as controls.
ScFv-Fc ToR67-3B4 caused a reduction of infectivity of vaccine
strain TC83 to 40% and was able to reduce VEEV infectivity of
Everglades virus (formerly subtype II) to 25%. Neutralization of
infectivity of both strains was only achieved with high concentra-
tions of antibody. However, scFv-Fc ToR67-3B4 was clearly not
able to neutralize the VEEV wildtype strain TrD (Figure 4).
Furthermore, the recombinant construct reduced the number of
plaques of Mucambo virus (strain BeAn8, formerly subtype IIIA)
and plaques of Everglades and Mucambo virus (formerly subtype
II and IIIA) produced in the presence of scFv-Fc ToR67-3B4 were
greatly reduced in size compared to the controls (data not shown).
Passive protection of mice in vivo
Mice have been widely used for studies of VEE pathogenesis,
testing of vaccines and therapeutic treatment. Infection by either
the intranasal or subcutaneous routes results in the invasion of the
central nervous system and 100% mortality [64–66].
Since a sufficient in vivo stability of an antibody is a basic
requirement for successfull protection in vivo, the half-life of
ToR67-3B4 in BALB/c mice was estimated before the recombi-
nant antibody was applied in virus challenge experiments. One-
hundred mg of the scFv-Fc were injected intraperitoneally and sera
were harvested from the murine marginal tail veins at 8 hours, 1,
3, 5, 10, 15 and 25 days post-administration. The serum antibody
concentration of the remaining scFv-Fc ToR67-3B4 in blood was
determined by ELISA and the recombinant antibody was no
longer detectable after 5 days (data not shown). The decrease in
antibody serum concentration over time resulted in a half-life of
1.68 d (95% confidence intervals: 1.65–1.71 d, data not shown)
that was considered as sufficient to justify analysing the therapeutic
potential of this construct.
Therefore, mice were exposed to VEEV strain TrD (subtype
IA/B), Mena II (subtype IE), Fe37c (formerly subtype II) and
Mucambo virus (strain BeAn8, formerly subtype IIIA) by the
aerosol route. Six to seventy-two hours later, 100 mg of scFv-Fc
ToR67-3B4 was administered intraperitoneally to a subset of mice
and mice were monitored for clinical signs of VEE for 14 days.
Naı ¨ve mice as well as mice treated with human IgG or a non-
specific recombinant antibody (anti-WEEV) did not survive the
challenge (median time to death, 6 d) but the recombinant
antibody was able to provide significant levels of protection to
infected mice (Figure 5) (P=0.0008, Mantel-Haenszel Logrank
test). When the recombinant antibody was administered 6 hours
post challenge with VEEV strains TrD or Mena II 80 to 100% of
mice survived but died within 6 to 7 days when antibodies were
applied after 24 hours or later. Forty to sixty % of mice survived
when scFv-Fc ToR67-3B4 was applied 6 hours post challenge with
VEEV strains Fe37c and Mucambo virus (strain BeAn8).
In order to ascertain that scFv-Fc ToR67-3B4 was able to
prevent viral infection, sera were harvested from the surviving
mice and analysed for VEEV-specific antibody by ELISA. A
murine-specific peroxidase-conjugated secondary antibody was
utilised to distinguish the response induced by the murine immune
system from scFv-Fc ToR67-3B4. All mice generated an immune
response to VEEV (results not shown), indicating that viral
infection had taken place. However, it is not known if this response
contributed to the survival of mice treated with scFv-Fc ToR67-
3B4.
Discussion
Screening and isolation of anti-VEEV antibody fragments from
a NHP antibody gene library by using phage display was
completed successfully. All selected binders shared the same
sequence which is not unusual for antibodies from immune
libraries containing affinity matured binders.
The scFv as well as the cognate Fc-fusion were able to detect
infectious as well as chemically inactivated VEEV viral antigen of
subtype IA/B. When applied as detection antibody scFv-Fc
ToR67-3B4 exhibited a broad immunological cross-reactivity to
Figure 3. Immunological analysis of VEEV glycoproteins. Panel
A and B show the immunoblot analysis of VEEV glycoproteins with scFv-
Fc ToR67-3B4 and monoclonal antibodies. Proteins from VEEV strain TC-
83 were either resolved on an 8–15% gradient (panel A) or a linear 12%
polyacrylamide gel (panel B) under denaturing and non-reducing
conditions at 56uC (panel A) or at 56uC and 95uC (panel B) under
denaturing conditions with or without 100 mM DTT. After Western
blotting the membrane was cut in stripes and was probed with either
scFv-Fc ToR67-3B4 (Panel A lane 2 and 6; panel B all lanes) or E1- and
E2-specific mAbs (Panel A lane 1 and 5: SFV 8/6 (E1-specific); lane 3:
WIS-VEE1 (E1-specific); lane 4: 1A3B7 (E2-specific)). Scale indicates
protein size in kDa. Panel C depicts the immunohistochemistry of Vero
cells infected with VEEV TrD, 1 day post infection. Photomicrographs
were obtained from infected (I–IV) and non–infected (V) cells with a
10fold magnification lens. Cells in panel I and II were stained for VEEV
antigen with biotinylated scFv-Fc ToR67-3B4, infected cells in panel III
and IV were detected with biotinylated mAb SFV 8/6 as positive control.
Non-infected Vero cells in panel V were stained with scFv-Fc ToR67-3B4
as negative control.
doi:10.1371/journal.pone.0037242.g003
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cross-reactivity to other Alphavirus species except for EEEV which
might be explained by the fact that VEEV is genetically less
distinct from EEEV than from SFV and WEEV [1,67]. In
combination with the subtype-specific mAb VEE WIS1 the strain
TC83 as representative of VEEV subtype IA/B was detected up to
at least aTCID50/ml of 10
6. In contrast, if scFv-Fc ToR67-3B4
was applied as capture antibody, the recombinant antibody
displayed a considerably broader cross-reactivity and identified
VEEV, EEEV and SFV as well. Furthermore, it showed a low
relative binding efficiency to CHIKV and WEEV.
Immunoblot analysis verified that scFv-Fc ToR67-3B4 recog-
nises specifically the viral E1 glycoprotein. We suppose that the Fc-
fusion detects a conformational rather than a linear epitope since a
specific staining of the viral envelope protein occurred after
denaturation at 56uC and 95uC under non-reducing but not under
reducing conditions. ScFv-Fc ToR67-3B4 seems to be one of the
rare and to our knowledge the first E1-specific scFv-fusion that was
able to neutralise virus infectivity in vitro for VEEV strains of
Figure 4. In vitro neutralisation activity of scFv-Fc fusion ToR67-3B4 to different VEEV strains and Everglades virus. VEEV strains of
subtype IA/B (Panel A and B) and Everglades virus (strain Fe37c, Panel C) with a TCID50/ml of 5610
4 were incubated with serial dilutions of scFv-Fc
ToR67-3B4 and other mAbs at 37uC for 2 hours. Starting concentrations were between 0.5 to 1.0 mg/ml. Subsequently the mixtures were subjected
to cell culture infection. Residual infectious activity of virus was estimated by specific immunostaining one day post infection with VEEV-specific
antibodies. Absorbance (OD450 nm) values obtained with virus samples not preincubated with any antibody served as positive control and were set
as 100% infectivity. Non-infected Vero cells were used as negative control. The mean values of two independent experiments are shown.
doi:10.1371/journal.pone.0037242.g004
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Whereas strains of subtype IA/B are epizootic, strains like Mena II
(subtype IE), Fe37c (Everglades virus, formerly subtype II) and
BeAn8 (Mucambo virus, formerly subtype IIIA) are enzootic and
induce a less progressive disease in mice. Moreover, infection with
enzootic strains is considered as non-lethal for human and equidae
[70,71]. Interestingly, scFv-Fc ToR67-3B4 was able to neutralise
virus infectivity of vaccine strain TC83 but failed to inactivate the
closely related wild type strain TrD although it bound well to it in
ELISA. The deduced amino acid sequences of the E1 glycoprotein
of strain TC83 and its parent strain TrD differ by a single amino
acid change. An introduction of genetic changes manifested at the
amino acid level caused by sequentially passaging over years as
described [72] was excluded by nucleic acid sequencing.
In the past, antibodies that specifically recognize and neutralise
VEEV in vitro and in vivo have been described. Most of them are
directed against the E2 protein, only a few targeted the viral E1
protein [61,62,69,73,78].
The neutralization efficiency of scFv-Fc ToR67-3B4 was less
than that of the two E2-targeting control antibodies mAb SFV 8/6
and 1A3B7. Moreover, incubation of virus with scFv-Fc ToR67-
3B4 had an influence on plaque morphology and size. Our data
support results of previous studies that clearly documented that
neutralisation efficiency for anti-E1 Fabs (fragment, antibody
binding) and mAbs are significantly lower than that for anti–E2
mAbs [36,37,61–63,74,75,79].
Interestingly, scFv-Fc ToR67-3B4 had potent ability to protect
mice from infection with VEEV subtype IA/B and IE, Everglades
and Mucambo virus (formerly subtypes II and IIIA) when
administered 6 hours post challenge but failed to cure mice if
applied 24, 48 or 72 hours post challenge. In addition, scFv-Fc
ToR67-3B4 was able to protect mice against challenge with
VEEV strain TrD although it failed to neutralise this virus strain in
vitro. Our results give evidence that protection against VEEV
disease by scFv-Fc ToR67-3B4 is not necessarily associated with
the ability to neutralise VEE virus. The findings reported here are
Figure 5. scFv-Fc ToR67-3B4 protects mice against VEEV disease. BALB/c mice were challenged by the aerosol route with approximately 100
LD50 VEEV strain TrD (Panel A and B), Mena II, Fe37c and Mucambo virus (BeAn8, Panel C and D). Six, twenty-four, forty-eight and seventy-two hours
later they were injected with 100 mg scFv-Fc ToR67-3B4 intraperitoneally (Panel A, B and C, n=6 or 10). As negative control mice remained either
untreated or were injected with a human IgG1 antibody (Panel B) or a nonspecific antibody (anti-WEEV, Panel D, n=10 or 5). Animals were observed
twice daily for clinical signs of infection and were culled when appropriate using humane endpoints.
doi:10.1371/journal.pone.0037242.g005
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suppose that scFv-Fc ToR67-3B4 binds to a critical site for cell
interaction of the VEEV virion either at the level of virus entry, or
budding. Whether complement or other Fc effector functions are
necessary in VEE virus immunity has to be analysed.
Furthermore, our results clearly indicate that the window in
which antibody therapy of VEE is efficacious is short
[36,37,61,62,68]. However, treatment offered a significant benefit
for mice as demonstrated in this study. Whether a similar effect in
mice is achieved if scFv-Fc ToR67-3B4 is used prophylactically,
has to be evaluated. The optimal time for administration of the
recombinant binder post challenge seems to be a matter of
antibody half-life and clearance. For scFv-Fc ToR67-3B4 the half
life was estimated to 1.68 days which is slightly lower than the half-
lives of two previously investigated antibodies [68,69].
Besides applications for specific detection and identification
purposes, the NHP antibody described here may have application
for human antiviral therapy. Database comparison of scFv
ToR67-3B4 indicated the highest similarity to the human
IGHV4-59*01 and IGKV2-30*01. Its variable regions were as
similar to human VHo rVL sequences as 24 and 7% present in
Kabat’s database respectively. Therefore, scFv ToR67-3B4 might
be regarded ‘‘as human’’ as these human sequences. Generally, a
high level of humanness is expected to correspond to decreased
immunogenicity and could be beneficial for therapeutic treatment
of VEE.
It may be even further improved by germline humanisation
which aims, without altering the antibody’s affinity, at suppressing
the macaque specific amino acids [81,82]. In addition, the human
constant regions utilized in the construction of the scFv-Fc could
even activate the human immune effectors better than their
murine counterparts and possibly allow an even better protection
in humans than seen in mice in the present study.
Previously chimeric, humanised and human antibodies have
successively been exploited as therapeutics in the murine model
but all these antibodies target the VEEV E2 glycoprotein
[61,62,68,69]. ToR67-3B4 is to our knowledge the first VEEV
inactivating scFv-Fc that targets the VEEV E1 glycoprotein and
we assume that the NHP antibody could provide enhanced
prophylaxis or immunotherapy for VEEV if used in combination
with the so far characterised neutralising E2-specific anti-VEEV
antibodies. Moreover, an antibody possessing reactivity to a wide
range of VEEV strains in vivo may be of benefit as a generic
antiviral therapy.
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